Skip Navigation

Adalvo announces successful DCP Submission for Pomalidomide Hard Capsules

11 August 2023

We are pleased to announce oursuccessful DCP submission for Pomalidomide Hard Capsules 1/2/3/4mg, upon expiry of the orphan market exclusivity.

Our product is based on the reference brand, Imnovid, and is indicated in the treatment of adult patients with multiple myeloma in combination with other medicinal products.

The brand sold approximately $2.28bn globally in 2022, having a significant growth potential with Global 3Y CAGR at 7%, according to IQVIA.

Adalvo currently holds marketing authorizations that are available to our esteemed partners across various global regions.

As a company committed to our oncology portfolio, Adalvo offers an array of dossiers and aims to assist our partners in overcoming any challenges that may arise with these mature products.

A glimpse into our varied oncology products include:

  • Afatinib Film-Coated Tablets
  • Azacitidine Tablets
  • Bosutinib Film-Coated Tablets
  • Cabozantinib Film-Coated Tablets
  • Ibrutinib Film Coated Tablets
  • Lenvatinib Hard Capsules
  • Midostaurin Capsules
  • Nintedanib Soft Gel Capsules
  • Palbociclib Film-Coated Tablets
  • Trametinib Tablets
  • Venetoclax Tablets

Partner up now! 

At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward. – Central & Eastern Europe, Russia & CIS - LATAM (exc. Brazil) North Europe, APAC, MENA & Israel – Brazil - LATAM (exc. Brazil) & South Europe – Europe – UK/Ireland, North America & South Africa - Head of Global BD&L

Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.